MedTrace Logo

Isotopic Imaging for Prodromal Alzheimer's Disease

NCT01231295 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 143

Last updated 2017-02-01

No results posted yet for this study

Summary

The primary objective of this study is to characterize cerebral metabolism modifications using 18F-FDG PET technology and perfusion with 99MTC-ECD SPECT in patients with prodromal Alzheimer's Disease drawn from a high risk population. We also compare PET and SPECT imaging within this framework, and search for optimal diagnostic thresholds.

Conditions

  • Alzheimer Disease

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nīmes

    lead OTHER

Principal Investigators

  • Pierre Olivier Kotzki, MD PhD · Centre Hospitalier Universitaire de Nîmes

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01231295 on ClinicalTrials.gov